Minireviews
Copyright ©The Author(s) 2019.
World J Gastroenterol. Sep 14, 2019; 25(34): 5097-5104
Published online Sep 14, 2019. doi: 10.3748/wjg.v25.i34.5097
Table 1 Main studies exploring very high dose vs standard proton pump inhibitors dose in Helicobacter pylori eradication regimens
StudyPPI comparisonAntibiotic regimenVery high dose eradication rate (%)Standard dose eradication rate (%)
De Francesco et al[16], 2016Esomeprazole 20 mg vs 40 mg bid14-d triple therapy (CLA+AMO)59/72 (81.9)54/73 (73.9)
Gisbert et al[23], 2005Esomeprazole 20 mg vs 40 mg bid7-d triple therapy (CLA+AMO)117/150 (78)111/150 (74)
Anagnostopoulos et al[24], 2004Omeprazole 20 mg vs esomeprazole 40mg bid7-d triple therapy (CLA+AMO)50/52 (96.1)37/52 (71.1)
Sheu et al[25], 2005Omeprazole 20 mg vs esomeprazole 40 mg bid7-d triple therapy (CLA+AMO)86/100 (86)79/100 (79)
Manes et al[26], 2005Omeprazole 20 mg vs omeprazole 40 mg bid7-d triple therapy (CLA+TNZ)132/161 (82)135/162 (83.3)
Choi et al[27], 2007Omeprazole 20 mg vs esomeprazole 40 mg bid7-d triple therapy (CLA+AMO)104/148 (70.3)290/428 (67.7)
Hu et al[28], 2017Rabeprazole 10 mg vs 20 mg qid14-d dual therapy (AMO)71/87 (81.6)68/87 (78.1)
Table 2 Randomized controlled trials comparing vonoprazan vs proton pump inhibitors for Helicobacter pylori eradication regimens
StudyProtocol in vonoprazan groupProtocol in PPI groupEradication rate in vonoprazan groupEradication rate in PPI group
Murakami et al[53], 2016Vonoprazan 20 mg bidLAN 30 mg AMO 750 mg bid299/329 (90.9%)241/321 (75.1%)
AMO 750 mg bidCLA 400 mg bid
CLA 400 mg bid
Maruyama et al[54], 2017Vonoprazan 20 mg bidLAN 30 mg or RAB 20 mg bid69/72 (95.8%)48/69 (69.6%)
AMO 750 mg bidAMO 750 mg bid
CLA 400 mg bidCLA 400 mg bid
Sue et al[55], 2018Vonoprazan 20 mg bidLAN 30 mg or RAB 10 mg or ESO 20 mg bid48/55 (87.3%)39/51 (76.5%)
AMO 750 mg bidAMO 750 mg bid
CLA 400 mg bidCLA 400 mg bid